✦ LIBER ✦

Quantitative risk-benefit analysis of oral phosphodiesterase type 5 inhibitors on erectile dysfunction treatment

✍ Scribed by Hsu, J.C.; Tang, D.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phosphodiesterase type 5 (PDE5) inhibito

✍ Dorsey, Philip; Keel, Christopher; Klavens, Meghan; Hellstrom, Wayne JG 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 298 KB

An update on pharmacological treatment o

✍ Bruzziches, Roberto; Francomano, Davide; Gareri, Pietro; Lenzi, Andrea; Aversa, 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 408 KB

UP-03.76: Evaluation of treatment of ere

✍ P. Chandrasekar; G. Krishnamoorthy; V. Sundarajan; B. Potluri 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Oral Phosphodiesterase-5 Inhibitors and

✍ Shindel, A. 📂 Article 📅 2010 🏛 Elsevier Science ⚖ 45 KB

Patterns of switching phosphodiesterase

✍ D. Hatzichristou; J. M. Haro; A. Martin-Morales; A. Von Keitz; A. Riley; J. Bert 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Phosphodiesterase type 5 inhibitors for

✍ Vickers, M A; Satyanarayana, R 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB